Targeting ERBB receptors in cancer.
Hynes
Nancy E
NE
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D008024:Ligands; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases